ECSP034891A - Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa - Google Patents

Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa

Info

Publication number
ECSP034891A
ECSP034891A EC2003004891A ECSP034891A ECSP034891A EC SP034891 A ECSP034891 A EC SP034891A EC 2003004891 A EC2003004891 A EC 2003004891A EC SP034891 A ECSP034891 A EC SP034891A EC SP034891 A ECSP034891 A EC SP034891A
Authority
EC
Ecuador
Prior art keywords
alkyl
derivatives
alkyloxy
independently
halogen
Prior art date
Application number
EC2003004891A
Other languages
English (en)
Inventor
Mingqiang Zhang
Simon James Anthony Grove
Mohammed Shahid
Original Assignee
Organon Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon Nv filed Critical Organon Nv
Publication of ECSP034891A publication Critical patent/ECSP034891A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D515/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • A61P25/12Antiepileptics; Anticonvulsants for grand-mal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a un derivado de benzoxazepina que tiene la fórmula general I, en la cual X representa CO o SO2; R1, R2, R3 y R4 son independientemente seleccionados desde H, (C 1-4) alquilo, (C 1-4) alquiloxi, (C 1-4)alquiloxi(C 1-4)alquilo, CF3, halógeno, nitro, ciano, NR8R9, NR8COR10, y CONR8R9; R5, R6 y R7 son independientemente H o (C 1-4)alquilo; R8 y R9 son independientemente H o (C 1-4)alquilo; o R8 y R9 forman junto con el átomo de nitrógeno al cual están unidos al anillo heterocíclico saturado membrado 5- o 6-, conteniendo opcionalmente un hetero átomo adicional seleccionado desde O, S, o NR11; R10 es (C 1-4)alquilo; R11 es (C 1-4)alquilo; A representa el residuo de un anillo heterocíclico saturado membrado 4-7, opcionalmente conteniendo un átomo de oxígeno, el anillo siendo opcionalmente sustituido con sustituyentes 1-3 seleccionados desde (C 1-4)alquilo, (C 1-4)alquiloxi, hidroxi, halógeno u oxo; o una sal farmacéuticamente aceptable del mismo. LA invención también e refiere a composiciones farmacéuticas que comprenden dichos derivados, y el uso de estos derivados de benzoxazepina en el tratamiento de enfermedades neurológicas y desórdenes psiquiátricos los cuales responden al aumento de las respuestas sinápticas intermediadas por los receptores AMPA en el sistema nervioso central.
EC2003004891A 2001-06-11 2003-12-11 Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa ECSP034891A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01202215 2001-06-11

Publications (1)

Publication Number Publication Date
ECSP034891A true ECSP034891A (es) 2004-01-28

Family

ID=8180450

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004891A ECSP034891A (es) 2001-06-11 2003-12-11 Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa

Country Status (29)

Country Link
US (2) US7307073B2 (es)
EP (1) EP1399450B1 (es)
JP (1) JP4435561B2 (es)
KR (1) KR100863255B1 (es)
CN (1) CN1257908C (es)
AR (1) AR036092A1 (es)
AT (1) ATE389659T1 (es)
AU (1) AU2002314144B2 (es)
BR (1) BR0210222A (es)
CA (1) CA2450274C (es)
CO (1) CO5550447A2 (es)
CZ (1) CZ300052B6 (es)
DE (1) DE60225689T2 (es)
EC (1) ECSP034891A (es)
ES (1) ES2301651T3 (es)
HR (1) HRP20031007A2 (es)
HU (1) HUP0400154A3 (es)
IL (2) IL158905A0 (es)
IS (1) IS2526B (es)
MX (1) MXPA03011563A (es)
NO (1) NO328705B1 (es)
NZ (1) NZ529670A (es)
PE (1) PE20030097A1 (es)
PL (1) PL366721A1 (es)
RU (1) RU2279434C2 (es)
SK (1) SK287150B6 (es)
TW (1) TWI232863B (es)
WO (1) WO2002100865A1 (es)
ZA (1) ZA200309382B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101029051B (zh) 2001-06-14 2010-06-09 欧加农股份有限公司 作为AMPA受体正性调节剂的(噻吩并)-[f]-氧杂吖庚因-5-酮衍生物
WO2010054336A2 (en) * 2008-11-10 2010-05-14 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
AR078187A1 (es) * 2009-09-28 2011-10-19 Hoffmann La Roche Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer.
FR2964969B1 (fr) * 2010-09-16 2012-08-24 Servier Lab Nouveaux derives dihydrobenzoxathiazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2915405A1 (en) 2013-06-13 2014-12-18 Veroscience Llc Compositions and methods for treating metabolic disorders
EP3436021A4 (en) 2016-03-29 2019-11-06 RespireRx Pharmaceuticals Inc. COMPOSITIONS AND METHODS FOR TREATING ATTENTION DEFICIT DISORDER
US10821103B2 (en) 2016-11-07 2020-11-03 Arbutus Biopharma Corporation Substituted pyridinone-containing trycyclic compounds, and methods using same
TWI801517B (zh) 2018-03-12 2023-05-11 加拿大商愛彼特生物製藥公司 經取代的2-吡啶酮三環化合物、其類似物及其使用方法
US11505551B2 (en) 2018-04-12 2022-11-22 Arbutus Biopharma Corporation Methods for preparing substituted pyridinone-containing tricyclic compounds
US12103936B2 (en) 2018-11-22 2024-10-01 Fujian Akeylink Biotechnology Co., Ltd. Crystal form of hepatitis B surface antigen inhibitor
US20230218632A1 (en) * 2020-03-20 2023-07-13 Amathus Therapeutics, Inc. Cyclic sulfonamide derivatives as trap1 modulators and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1238719A (es) 1968-11-01 1971-07-07
DK1156043T3 (da) 1992-07-24 2004-03-01 Univ California Lægemidler, der forøger synaptiske reaktioner formidlet af ampa-receptorer
US6174881B1 (en) * 1995-01-06 2001-01-16 Hoffman-La Roche Inc. Hydroxymethylimidazodiazepines and their esters
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
EP0884310B1 (en) 1997-06-09 2005-09-07 Pfizer Products Inc. Quinazolin-4-one ampa antagonists
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
RU2214405C2 (ru) * 1998-02-18 2003-10-20 НьюроСёрч А/С Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов
US6124278A (en) 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response

Also Published As

Publication number Publication date
SK15182003A3 (sk) 2004-05-04
AR036092A1 (es) 2004-08-11
IL158905A0 (en) 2004-05-12
ZA200309382B (en) 2005-03-02
IL158905A (en) 2008-12-29
HUP0400154A3 (en) 2007-05-02
US20080139529A1 (en) 2008-06-12
DE60225689D1 (de) 2008-04-30
CN1514835A (zh) 2004-07-21
IS2526B (is) 2009-07-15
DE60225689T2 (de) 2008-07-17
US20040171605A1 (en) 2004-09-02
JP2004533466A (ja) 2004-11-04
CA2450274C (en) 2010-12-21
HK1061858A1 (en) 2004-10-08
CA2450274A1 (en) 2002-12-19
ATE389659T1 (de) 2008-04-15
HUP0400154A2 (hu) 2004-07-28
KR20040006030A (ko) 2004-01-16
AU2002314144B2 (en) 2008-01-31
SK287150B6 (sk) 2010-01-07
RU2279434C2 (ru) 2006-07-10
ES2301651T3 (es) 2008-07-01
WO2002100865A1 (en) 2002-12-19
EP1399450A1 (en) 2004-03-24
MXPA03011563A (es) 2004-03-18
CO5550447A2 (es) 2005-08-31
HRP20031007A2 (en) 2005-10-31
PL366721A1 (en) 2005-02-07
EP1399450B1 (en) 2008-03-19
KR100863255B1 (ko) 2008-10-15
NO20035486D0 (no) 2003-12-10
TWI232863B (en) 2005-05-21
US7504390B2 (en) 2009-03-17
CN1257908C (zh) 2006-05-31
US7307073B2 (en) 2007-12-11
CZ20033376A3 (en) 2004-04-14
RU2004100310A (ru) 2005-06-10
BR0210222A (pt) 2004-04-13
IS7036A (is) 2003-11-13
NO328705B1 (no) 2010-05-03
NZ529670A (en) 2006-02-24
CZ300052B6 (cs) 2009-01-21
PE20030097A1 (es) 2003-02-08
JP4435561B2 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
CY1109558T1 (el) Παραγωγα βενζο[d]αζεπινης για την θεραπεια νευρολογικων διαταραχων
ECSP045368A (es) "antagonistas de los receptores de trombina"
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
AR037647A1 (es) Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
ES2164657T3 (es) Derivados aza-biciclicos puenteados como antagonistas de la sustancia p.
ES2184772T3 (es) Derivados de bifenilo, procedimiento para su preparacion y su utilizacion como medicamentos.
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
CO5031253A1 (es) Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen
PE20020470A1 (es) Derivados de pirazol como inhibidores de las enzimas proteina quinasas
AR035774A1 (es) Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento
BG101806A (bg) Индолови производни като антагонисти на 5-нт рецептори
UY28150A1 (es) Agentes terapeuticos
AR042668A1 (es) Derivados de fosfonoxi quinazolinas y su uso farmaceutico
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
PA8456901A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
AR052943A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
DE602006006850D1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
ECSP034891A (es) Derivados de benzoxazepina y su uso como estimula_ dores de receptores ampa
PE20050141A1 (es) DERIVADOS DE 2-ALQUINIL-Y 2-ALQUENIL-PIRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PIRIDINA COMO ANTAGONISTAS DEL RECEPTOR A2a ADENOSINA
PE54294A1 (es) Derivado de 5-aminoalquil-1,4-benzodiazepina
AR029214A1 (es) Compuestos inhibidores de fosfodiesterasa - 4: 8 - arilquinolinas sustituidas, composiciones farmaceuticas, metodo de tratamiento que las utiliza
DE602006019221D1 (de) Von dopamin-d3-rezeptoren